ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways.

Lin, Sheng-Li

ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways. [electronic resource] - PloS one Feb 2010 - e9013 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1932-6203

10.1371/journal.pone.0009013 doi


Alternative Splicing
Antineoplastic Agents, Hormonal--pharmacology
Blotting, Western
Butadienes--pharmacology
Cell Line, Tumor
Cell Membrane--metabolism
Cell Proliferation--drug effects
Chromones--pharmacology
Dose-Response Relationship, Drug
Endometrial Neoplasms--genetics
Enzyme Activation--drug effects
Estrogen Receptor alpha--agonists
Estrogens--pharmacology
Extracellular Signal-Regulated MAP Kinases--antagonists & inhibitors
Female
Humans
Morpholines--pharmacology
Nitriles--pharmacology
Phosphatidylinositol 3-Kinases--metabolism
Phosphoinositide-3 Kinase Inhibitors
Protein Isoforms--agonists
Proto-Oncogene Proteins c-akt--metabolism
Proto-Oncogene Proteins c-myc--metabolism
RNA Interference
Signal Transduction--drug effects
Tamoxifen--pharmacology